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Abstract
The notion that psychosis may exist on a continuum with normal experience has been proposed in 
multiple forms throughout the history of psychiatry. However, in recent years there has been an 
exponential increase in efforts aimed at elucidating what has been termed the ‘psychosis 
continuum’. The present review seeks to summarize some of the more basic characteristics of this 
continuum and to present some of the recent findings that provide support for its validity. While 
there is still considerable work to be done, the emerging data holds considerable promise for 
advancing our understanding of both risk and resilience to psychiatric disorders characterized by 
psychosis.
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Introduction
The idea that psychosis may exist on a continuum with normal experience has been 
proposed in multiple forms throughout the history of psychiatry [1]. Over the last 20 years, 
however, there has been an exponential increase in efforts aimed at elucidating what has 
been termed the ‘psychosis continuum’ [2]. While the origin of this increased interest is 
complex and beyond the scope of the present review, the outcome has been to induce a 
lively [see 3 and accompanying commentary] and in some cases, divisive [see 4 and 
accompanying commentary] debate about the existence and form of this continuum. Much 
of the criticism directed at the study of the psychosis continuum has centered around 
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concerns that such theories may serve to blur the existing diagnostic categories. However, as 
aptly pointed out by Kaymaz and van Os [5], the idea that psychotic experiences occur in the 
general population can only undermine diagnostic categories if “diagnoses like 
‘schizophrenia’ represent valid nosological entities”; an issue that is rigorously debated in 
the field (i.e. 6]. Perhaps a more valid point of contention regarding the utility of studying 
the psychosis continuum is whether it provides a better opportunity for elucidating the 
pathophysiology of psychosis than the current approach of biologically dissecting 
heterogeneous categories [4]. We would argue, however, that both approaches are needed 
and may serve complementary roles in untangling the complex architecture of psychotic 
disorders. Specifically, while the study of heterogeneous patient samples offers 
opportunities to examine the pathophysiology underlying risk for psychotic disorders, the 
examination of otherwise healthy individuals who exhibit sub-syndromal psychotic 
symptoms but who do not meet criteria for a psychiatric disorder offers opportunities to 
examine the pathophysiology of resilience to these disorders.
Defining the Psychosis Continuum
The psychosis continuum encompasses a full range of psychotic symptom expressions from 
sub-syndromal or “subclinical” manifestations to the clinically significant psychotic 
symptoms typically observed in individuals diagnosed with a psychiatric illness. Subclinical 
psychotic symptoms such as ideational thinking or altered perceptual experiences are often 
distinguishable from clinically significant psychotic symptoms such as delusions and 
hallucinations, based on features of the symptoms themselves such as severity, frequency, 
and conviction [7]. However, in some cases the features of subclinical psychotic symptoms 
may, at least in some ways, be indistinguishable from the features of psychotic symptoms 
observed in patients with psychiatric illness. For example, Johns and colleagues [*8] 
recently reviewed the available data on auditory verbal hallucinations (AVH) in otherwise 
healthy individuals and compared them to data on patients with psychotic illness. Although 
they noted differences in the emotional valence of these experiences as well as differences in 
the appraisals and behavioral responses to these experiences, they noted very few 
differences in the basic qualities (i.e. severity, frequency, conviction) of the AVH between 
the non-clinical and clinical samples.
Modern approaches to the study of the psychosis continuum derive from two primary 
models that differ most notably in their predictions about the frequency of subclinical 
symptoms across the full population. The Quasi-Dimensional Model derives primarily from 
the work of Meehl [9, 10] who suggested that a “dominant autosomal schizogene” produced 
an aberration in synaptic signal selectivity that produced a defect in neurointegrative 
processes that he called “schizotaxia”. Meehl [10] asserted that under certain circumstances, 
schizotaxia gave rise to schizotypy, “a personality showing ambivalence, aversive drift, 
dereism, autism, and cognitive slippage” and that schizotypy was a necessary, but not 
sufficient, precursor for the emergence of schizophrenia. In this way, the Quasi-Dimensional 
Model posits a continuum of psychosis ranging from aberrant personality characteristics (i.e. 
magical thinking) to the clinically significant psychotic symptoms associated with psychotic 
disorders (i.e. delusions). Notably, however, Meehl believed that only ~10% of the 
population carried the “schizogene” and thus, only a small percentage of the population 
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could be represented across the psychosis continuum. While it is now clear that psychotic 
disorders are genetically complex, likely involving thousands of genetic variants rather than 
a single fully-penetrant risk allele [11], Meehl’s Quasi-Dimensional Model is at least partly 
supported by data derived from studies of schizotypal personality [For an excellent review 
of these data see 12]. In contrast, the Fully Dimensional Model, which derives primarily 
from the work of Claridge [13, 14], assumes that psychotic symptoms exists along a 
continuum across the full population. In Claridge’s view, symptoms of psychosis may be 
adaptive or detrimental depending on simultaneous variation along some other dimensional 
characteristic (i.e. intelligence). For example, he noted that highly creative individuals 
displayed many symptoms characteristic of schizophrenia (i.e. withdrawal, emotional 
instability, eccentricity, etc.). However, although a very creative healthy individual may be 
predisposed to schizophrenia, they do “not become clinically psychotic because high general 
intelligence confers some immunity in the form of adequate intellectual and personality 
reserves” [14].
It is not yet clear which model, Quasi- or Fully-Dimensional, best fits the available data. In 
practice, however, much of the recent work seeking to elucidate the psychosis continuum 
ascribes to one model or the other based solely on the operational definitions of subclinical 
psychotic symptoms. For example, while the Schizotypal Personality Questionnaire (SPQ) 
[15] is generally viewed as a measure based on the Quasi-dimensional Model, the 
Community Assessment of Psychic Experiences (CAPE) [16] is generally viewed as a 
measure based on the Fully Dimensional Model. However, little is known about the extent 
to which measurements derived from these scales differ from one another. Indeed 
throughout much of the literature, symptoms assessed in otherwise healthy individuals using 
these (and a multitude of other) scales are typically collectively referred interchangeably as 
schizotypy and subclinical psychotic symptoms.
Epidemiology
Subclinical psychotic symptoms are common in the general population. They have an 
estimated prevalence of 7.2%, with prevalence of specific symptoms ranging from 4.8% for 
delusions of control to 8.4% for delusions of reference and persecution [17], and an annual 
incidence of 2.5% [**18]. Although these rates are nearly double that of psychotic disorders 
[19], data suggest a functional relationship between the rates of subclinical symptoms and 
psychotic disorders in a given population. For example, in a random population study of 
over 7,000 individuals, van Os and colleagues [20] found that as the rate of psychotic 
disorders increased as a function of greater levels of urbanicity in 5 distinct regions ranging 
from very rural to very urban, the level of subclinical symptoms in the healthy populations 
within the same regions also increased in a dose–dependent fashion. These data suggest that 
subclinical symptoms, even at a gross population level, bear a linear relationship to 
clinically significant psychotic symptoms and may suggest that they represent the behavioral 
expression of an underlying predisposition for psychotic disorders.
Notably, epidemiological studies also suggest that the prevalence of subclinical psychotic 
symptoms during late childhood and adolescence is exponentially higher than in adult 
populations with estimates generally between 40% and 66% [21, 22]. Moreover, evidence 
DeRosse and Karlsgodt Page 3
Curr Behav Neurosci Rep. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
suggests that subclinical psychotic symptoms are age related, peaking in adolescence and 
decreasing thereafter [23–25]. The extraordinarily high prevalence of subclinical psychotic 
symptoms during late childhood and adolescence has led to the suggestion that these 
symptoms may represent the behavioral expression of normal neurodevelopmental processes 
[26]. However, prospective longitudinal studies have demonstrated that high levels of 
subclinical psychotic symptoms often predict, albeit weakly, the onset of later psychiatric 
illness. For example, Chapman and colleagues [27] initially demonstrated that individuals 
who were rated high on scales of magical ideation and perceptual aberration had high rates 
of psychotic outcomes 10 years later and Poulton et al [28] found that 25% of children with 
psychotic experiences at age 11 developed schizophreniform disorder over a 16-year follow-
up period. These results have been further replicated in several distinct cohorts [29–32] and 
collectively suggest some continuity between subclinical and clinically significant psychotic 
symptoms.
Evidence for Similarity Between Subclinical and Clinically Significant 
Psychosis
The evidence supporting the continuity from subclinical to clinically significant psychotic 
symptoms derives from multiple sources including 1) data demonstrating similarities in the 
clinical profiles of patients with psychotic disorders and healthy individuals who report 
subclinical psychotic symptoms, 2) substantial overlap in demographic and experiential risk 
factors for psychotic disorders and subclinical psychotic symptoms as well as 3) evidence 
derived from family-based and molecular genetic studies. Moreover, data from brain 
imaging studies has recently begun to emerge suggesting that there may also be overlap in 
the structural and functional correlates of psychotic symptoms across the psychosis 
continuum. The following sections represent a selective review of some of the more recent 
findings in these areas.
Clinical Profiles
A critical issue that has received scant attention in the literature is whether or not the 
psychotic symptoms assessed in healthy samples bear a resemblance to the psychotic 
symptoms assessed in patient samples. Indeed, we are not aware of a single study whose 
primary aim was to directly compare patient and healthy samples on the same measure of 
psychotic symptoms. Data derived from our ongoing studies, however, provide at least some 
evidence for overlap in the symptom dimensions measured in these two samples 
[unpublished data]. Figure 1 shows preliminary data from both healthy individuals and 
stable outpatients with schizophrenia or schizoaffective disorder assessed using the CAPE. 
We have previously demonstrated the validity of self-reported symptoms as measured by the 
CAPE subscales in the patient sample by comparing them to scores obtained on standard 
clinician-administered rating scales [33]. As the figure illustrates, there is considerable 
overlap in the distribution of symptom scores across these samples. Notably, permutation 
testing on the skewness of the patient vs. healthy distributions for both positive and negative 
symptoms reveal that the shapes of the distributions do not significantly differ, despite the 
obvious difference in mean scores.
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Considerably more attention has been directed to examining similarities in comorbid 
symptoms in patient and healthy samples. Specifically, a large body of work has sought to 
examine whether the high rate of comorbid depressive symptoms observed in patients with 
psychotic disorders is evidenced at the subclinical end of the psychosis continuum. These 
efforts have revealed that in both adults [34] and adolescents [35–37], subclinical psychotic 
and depressive symptoms are significantly interrelated; although they may not be predictive 
of one another longitudinally [37]. Recent data from Klaassen and colleagues [38] provide 
direct support for the overlap between psychotic and depressive symptoms across the 
continuum. Specifically, they demonstrated in a large sample of patients, healthy siblings 
and healthy controls that the number and duration of depressive symptoms was significantly 
associated with the severity of psychotic symptoms in all three groups.
The overlap in clinical symptom profiles between psychotic disorders and subclinical 
psychotic symptoms also extends to premorbid personality characteristics. Specifically, 
similar patterns of personality traits have been observed between clinically significant 
psychosis phenotypes, including schizophrenia and schizotypal personality disorder [39–41] 
and dimensions of schizotypy in otherwise healthy individuals [42–45]. Indeed, the concept 
of schizotypy [9, 46–47] has considered psychosis-proneness as a personality framework 
itself [42, 48] and studies using a range of personality measures have identified a consistent 
pattern of personality traits that are shared between patients exhibiting clinically significant 
psychotic symptoms and otherwise healthy individuals who exhibit high levels of 
schizotypal or subclinical symptoms. For example, studies using Cloninger’s temperament 
and character inventory (TCI) [49] have found that both groups score high on harm 
avoidance and self-transcendence as well as low on reward dependence, novelty seeking, 
self-directedness, and cooperativeness [43, 50–52].
Although the overlap in personality profiles noted above may provide some insight into risk 
for psychotic disorders, we have recently identified some differences between the 
personality profiles of patients with psychotic disorders and otherwise healthy individuals 
who exhibit high levels of schizotypy. Specifically, while previous work found patients with 
schizophrenia were characterized by low persistence and low cooperativeness, in a sample 
of 415 healthy individuals we found that high persistence was linked with high levels of 
positive subclinical symptoms and high cooperativeness was linked with high levels of 
negative subclinical symptoms [52]. These findings may suggest some potential resilience 
factors that separate those on the subclinical end of the psychosis continuum from patients 
with psychotic disorders. Specifically, it is possible that higher persistence confers a greater 
ability to overcome the adversity associated with positive symptoms and higher 
cooperativeness confers a greater capacity to resist tendencies towards social withdrawal and 
a greater ability to accept social support from others. Thus, these personality traits may act 
to mitigate the risk of transition from subclinical to clinically significant psychosis. 
Although these results have not yet been replicated, these preliminary findings suggest that 
the comparison of patients with clinically significant psychotic symptoms to otherwise 
healthy individuals with high levels of subclinical psychotic symptoms may provide some 
insight into the mechanisms of resilience to psychotic disorders.
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Neurocognition
These observed similarities in clinical profiles between subclinical psychosis and clinically 
significant psychotic disorders have prompted some researchers to hypothesize that 
neurocognitive deficits might also show a dose-response relationship across the psychosis 
continuum. Deficits across a range of cognitive skills have increasingly been recognized as a 
core feature of psychotic illness, with cognitive deficits manifesting in schizophrenia, 
schizotypal personality disorder, and schizophrenia patients’ unaffected first degree relatives 
[53–55]. However, despite large-scale longitudinal birth-cohort data implicating deficits in 
general cognitive function [g] at ages 8, 11, and 15 in the manifestation of later subclinical 
psychotic symptoms in middle age [56], cross-sectional studies investigating the role of 
subclinical psychosis in neurocognitive performance have produced inconsistent results. 
While some studies have linked subclinical psychosis to deficits in cognitive function 
including visual memory and visuoconstructive performance [57], verbal fluency [58–60], 
working memory [61], selective and sustained attention [60, 62–65], cognitive set shifting 
[66], and capacity for abstract reasoning [66], other studies have found no significant links 
between subclinical psychosis and performance deficits in these cognitive areas [67–73]. 
Many of these studies, however, have been limited by small sample sizes, inclusion of only 
college students, inconsistent definitions of subclinical psychosis and a lack of consistency 
in the cognitive domains examined.
More recently, our group [74] reported the results of data derived from a large (n=303) and 
demographically diverse non-clinical sample in which we examined the relationship 
between sub-syndromal positive and negative psychotic symptoms and performance on the 
MATRICS Consensus Cognitive Battery (MCCB), a test battery designed specifically to 
assess cognitive domains that are reliably impaired in psychotic disorders [75]. We found 
that high levels of positive subclinical psychotic symptoms was associated with significantly 
better performance on measures of working memory, verbal learning, and visual learning as 
measured by the MCCB. Moreover, those who scored high on negative subclinical psychotic 
symptoms evidenced significantly better performance on a measure of general cognitive 
ability (WRAT-3). These results are in line with the idea that higher cognitive capacities 
may act as a resilience factor against clinically significant psychosis [14, 76–77]. 
Specifically, data suggests that the risk of transitioning from subclinical to clinically 
significant psychotic symptoms is significantly associated with impaired neurocognitive 
function [78]. Conversely, it is possible that better cognitive function acts as a protective 
mechanism to prevent such a transition. Although these findings will require replication in 
larger samples, these preliminary findings also highlight the potential utility of examining 
the psychosis continuum for the identification of potential resiliency factors.
Risk Factors
A recent review and meta-analysis of the literature on subclinical psychosis in healthy 
populations spanning over 2 decades [**18] found that nearly all of the demographic and 
experiential risk factors for psychotic disorders predicted greater risk of subclinical 
psychotic symptoms in otherwise healthy individuals. Due to limited space, however, we 
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will limit the present review to a single risk factor that has recently received the lions-share 
of attention in the literature.
Childhood Trauma
Several studies have demonstrated an association between childhood maltreatment and 
psychotic disorders and a recent review and meta-analysis of these studies [79] found that 
childhood adversity is substantially associated with an increased risk for psychosis with a 
population attributable risk of ~33%. A substantial body of literature support the extension 
of this relationship to subclinical psychotic symptoms. For example, Kelleher and colleagues 
[80] recently demonstrated a dose-response relationship between childhood trauma and 
psychotic experiences in a large prospective cohort of adolescents followed over a 12-month 
period. Specifically, they found that the odds of psychotic experiences increased in line with 
increasing levels of bullying and physical assault. These data are consistent with findings 
suggesting that patients with psychotic disorders often have a more severe history of 
childhood maltreatment than healthy individuals [81]. More recently, our group [33] 
compared the strength of the association between childhood maltreatment and self-reported 
psychotic symptoms in 447 healthy adult volunteers and 184 stable outpatients with 
schizophrenia or schizoaffective disorder and found very significant positive correlations 
between childhood maltreatment and self-reported symptoms in both groups. Notably, 
although patients scored significantly higher than controls on both history of childhood 
maltreatment and self-reported symptoms, the strength of the relationship [based on the 
resulting regression lines] did not differ between groups. Collectively, these data suggest 
that the experience of maltreatment during childhood may create a biological [82] or 
psychological [83] vulnerability for the development of psychotic symptoms along a 
continuum [84].
Genetics
Early work in large-scale family-based genetic studies [85–88] demonstrated an increased 
incidence of subclinical psychotic symptoms in the relatives of patients with schizophrenia 
and unselected, population-based twin studies also showed substantial genetic contributions 
to subclinical symptoms [89–91]. Although somewhat limited, recent data seeking to 
elucidate the molecular genetic underpinnings of psychotic symptoms provide some 
preliminary support for the psychosis continuum.
Genetic Association Studies
The first direct study of the role of genetic variants in the expression of sub-syndromal 
psychotic symptoms was reported by Avramopoulos and colleagues [92]. They found that 
the healthy young males who carried the val allele at the catechol-O-Methyltransferase 
[COMT] Val158Met loci, which is associated with high enzymatic activity, reported higher 
scores on a measure of schizotypy than those carrying the met allele. Additional work 
examining variation in COMT has largely supported this initial finding [93–95]. More 
recently, several genetic variants originally identified as risk variants for schizophrenia have 
also been shown to relate to measures of subclinical psychotic symptoms. For example, 
variants in the Calcium channel, voltage-dependent, L type, alpha 1C subunit gene 
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[CACNA1C], that have repeatedly been associated with schizophrenia [96] and bipolar 
disorder [97] have recently been associated with paranoid ideation in otherwise healthy 
participants [98]. Additionally, Stefanis and colleagues [99] found that common variants of 
the gene encoding zinc-finger protein 804A [ZNF804A], also strongly associated with 
schizophrenia and bipolar disorder [100], were associated with paranoia and ideas of 
reference in otherwise healthy young males. Finally, Tomppo et al [101] found that in a 
large population-based epidemiological sample, a variant in the Disrupted in Schizophrenia 
1 [DISC1] gene was significantly associated with the severity of negative symptoms. 
Collectively, these data suggest that genetic variation may, at least in some way, contribute 
to the expression of psychotic symptoms across the continuum.
Neuroimaging
There is a relatively small literature using neuroimaging to explore the neural basis of 
subclinical psychosis. The majority of papers have employed structural magnetic resonance 
imaging (sMRI) techniques to assess individual differences in gray matter (GM) volume, 
and thickness. Decreased GM volume has been reported in the frontal and temporal lobes 
including the pars orbitalis and rostral middle frontal cortex [102], the lateral and medial 
orbital frontal cortex [103], the inferior temporal gyrus [104], and the left and right putamen 
[105], with decreased cortical thickness observed in temporal regions [119]. However, there 
have also been reports of increased volume and thickness, with Jacobsen and colleagues 
[104], reporting larger GM volume in middle and superior temporal gyri, the angular gyrus, 
and orbitofrontal cortex in at-risk children, and Cordova-Palomera and colleagues [106] 
showing relationships between symptom scores with cortical thickness that varied based on 
season of birth, an environmental risk factor.
White matter in subclinical psychosis has been assessed using volumetric measures as well 
as diffusion tensor imaging (DTI). Decreases in fractional anisotropy (FA), a putative 
measure of white matter integrity, have been described in the inferior frontal occipital 
fasciculus [119, 121], as well as the cingulum bundle and inferior longitudinal fasciculus 
[119]. Moreover, the level of hallucinatory symptoms experienced by patients, their 
unaffected siblings, and healthy controls all showed a negative correlation with whole-brain 
FA [107]. However, in patients with schizophrenia, relatives, and individuals with 
schizotypal features, symptomatology also showed a specific positive relationship with the 
arcuate fasciculus [107–108]. The uncinate fasciculus, a fronto-temporal tract, has shown 
mixed results, with findings of either increased FA on the left [108], or increased asymmetry 
such that the right hemisphere had higher FA than the left [102].
There have been relatively few functional investigations, these have demonstrated 
differences in functional magnetic resonance imaging (fMRI) activation during Theory of 
Mind [109], emotional processing [110], and social reflection [111] as well as differences in 
between network functional connectivity during resting state fMRI [*112]. Finally, a 
positron emission tomography (PET) investigation revealed no difference in dopamine 
synthesis capacity in healthy individuals who experienced hallucinations [113].
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In the existing neuroimaging work there is substantial variability in age, as well as 
diagnostic approach. The most common clinical method for ascertainment of subclinical 
samples for imaging appears to be the CAPE [103, 105, 106, 109, 110,]. However, other 
methods such as structured clinical interviews and scales focused on specific symptom 
domains have also been employed. In general, the field of neuroimaging in subclinical 
psychosis is in the early stages, and while there is evidence for decreases in GM, decreases 
in FA, and alterations in functional activation, the presence of conflicting findings even 
within this small literature highlights the clear need for further research in this area.
Conclusions
Collectively, the work reviewed here provides considerable support for a view of psychosis 
as a phenotype that can be examined across a continuum in general population samples. 
However, as recently reviewed by Kwapil and Vidal [12], the study of the symptoms 
comprising the psychosis continuum has been hindered by the lack of clearly defined 
constructs and the absence of a consensus model of how these symptoms relate to psychotic 
illness. Nevertheless, the emerging data holds considerable promise for advancing our 
understanding of both risk and resilience to psychiatric disorders characterized by psychosis 
that would not be possible through the study of patient samples alone.
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Figure 1. 
Distribution of scores on the Community Assessment of Psychic Experiences (CAPE) in 
healthy volunteers and patients with schizophrenia or schizoaffective disorder. Patients were 
stable (no hospitalizations in previous 6 months) at the time of the assessment. Panel A 
shows the distribution of positive symptoms. Panel B shows the distribution of negative 
symptoms.
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